BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). BioMarin expects to report results in the first half of 2012...

Read the original post at Psychology / Psychiatry News From Medical News Today ...